This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, J M Articles by Bonner, D P Search for Related Content PubMed PubMed Citation Articles by Clark, J M Articles by Bonner, D P

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 April; 35(4): 615-621

Amphotericin B lipid complex therapy of experimental fungal infections in mice.

Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000.

ABSTRACT

The amphotericin B lipid complex (ABLC), which is composed of amphotericin B and the phospholipids dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol, was evaluated for its acute toxicity in mice and for its efficacy in mice infected with a variety of fungal pathogens. ABLC was markedly less toxic to mice when it was administered intravenously; it had a 50% lethal dose of greater than 40 mg/kg compared with a 50% lethal dose of 3 mg/kg for Fungizone, the desoxycholate form of amphotericin B. ABLC was efficacious against systemic infections in mice caused by Candida albicans, Candida species other than C. albicans, Cryptococcus neoformans, and Histoplasma capsulatum. ABLC was also efficacious in immunocompromised animals infected with C. albicans, Aspergillus fumigatus, and H. capsulatum. Against some infections, the efficacy of ABLC was comparable to that of Fungizone, while against other infections Fungizone was two- to fourfold more effective than ABLC. Against several infections. Fungizone could not be given at therapeutic levels because of intravenous toxicity. ABLC, with its reduced toxicity, could be administered at drug levels capable of giving a therapeutic response. ABLC should be of value in the treatment of severe fungal infections in humans.

This article has been cited by other articles:

• Vallon-Eberhard, A., Makovitzki, A., Beauvais, A., Latge, J.-P., Jung, S., Shai, Y. (2008). Efficient Clearance of Aspergillus fumigatus in Murine Lungs by an Ultrashort Antimicrobial Lipopeptide, Palmitoyl-Lys-Ala-DAla-Lys. Antimicrob. Agents Chemother. 52: 3118-3126 [Abstract] [Full Text]  
• Olson, J. A., Adler-Moore, J. P., Jensen, G. M., Schwartz, J., Dignani, M. C., Proffitt, R. T. (2008). Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products. Antimicrob. Agents Chemother. 52: 259-268 [Abstract] [Full Text]  
• Olson, J. A., Adler-Moore, J. P., Schwartz, J., Jensen, G. M., Proffitt, R. T. (2006). Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.. Antimicrob. Agents Chemother. 50: 2122-2131 [Abstract] [Full Text]  
• Imai, J., Singh, G., Fernandez, B., Clemons, K. V., Stevens, D. A. (2005). Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 56: 166-171 [Abstract] [Full Text]  
• Clemons, K. V., Stevens, D. A. (2004). Comparative Efficacies of Four Amphotericin B Formulations--Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet--against Systemic Murine Aspergillosis. Antimicrob. Agents Chemother. 48: 1047-1050 [Abstract] [Full Text]  
• MacCallum, D. M., Odds, F. C. (2002). Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. J Antimicrob Chemother 50: 219-224 [Abstract] [Full Text]  
• Odds, F. C., Oris, M., Van Dorsselaer, P., Van Gerven, F. (2000). Activities of an Intravenous Formulation of Itraconazole in Experimental Disseminated Aspergillus, Candida, and Cryptococcus Infections. Antimicrob. Agents Chemother. 44: 3180-3183 [Abstract] [Full Text]  
• Warn, P. A., Morrissey, J., Moore, C. B., Denning, D. W. (2000). In Vivo Activity of Amphotericin B Lipid Complex in Immunocompromised Mice against Fluconazole-Resistant or Fluconazole-Susceptible Candida tropicalis. Antimicrob. Agents Chemother. 44: 2664-2671 [Abstract] [Full Text]  
• Van Etten, E. W. M., Stearne-Cullen, L. E. T., Ten Kate, M. T., Bakker-Woudenberg, I. A. J. M. (2000). Efficacy of Liposomal Amphotericin B with Prolonged Circulation in Blood in Treatment of Severe Pulmonary Aspergillosis in Leukopenic Rats. Antimicrob. Agents Chemother. 44: 540-545 [Abstract] [Full Text]  
• Machard, S., Theodoro, F., Benech, H., Grognet, J.-M., Ezan, E. (2000). A Sensitive Amphotericin B Immunoassay for Pharmacokinetic and Distribution Studies. Antimicrob. Agents Chemother. 44: 546-550 [Abstract] [Full Text]  
• Groll, A. H., Mickiene, D., Piscitelli, S. C., Walsh, T. J. (2000). Distribution of Lipid Formulations of Amphotericin B into Bone Marrow and Fat Tissue in Rabbits. Antimicrob. Agents Chemother. 44: 408-410 [Abstract] [Full Text]  
• Latge, J.-P. (1999). Aspergillus fumigatus and Aspergillosis. Clin. Microbiol. Rev. 12: 310-350 [Abstract] [Full Text]  
• Otsubo, T., Maesaki, S., Hossain, M. A., Yamamoto, Y., Tomono, K., Tashiro, T., Seki, J., Tomii, Y., Sonoke, S., Kohno, S. (1999). In Vitro and In Vivo Activities of NS-718, a New Lipid Nanosphere Incorporating Amphotericin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. 43: 471-475 [Abstract] [Full Text]  
• Swenson, C. E., Perkins, W. R., Roberts, P., Ahmad, I., Stevens, R., Stevens, D. A., Janoff, A. S. (1998). In Vitro and In Vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important?. Antimicrob. Agents Chemother. 42: 767-771 [Abstract] [Full Text]  
• Clemons, K. V., Stevens, D. A. (1998). Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for Treatment of Systemic Murine Cryptococcosis. Antimicrob. Agents Chemother. 42: 899-902 [Abstract] [Full Text]